Dalosirvat (SM-04554)

1. November 2018
   Phase 2→Phase 2/3

   First Phase 2/3 trial on record: NCT03742518 — A Study Evaluating the Efficacy and Safety of SM04554 Topical Solution in Male Subjects With Androgenetic Alopecia

   ClinicalTrials.gov ↗
2. November 2014
   Phase 2

   First Phase 2 trial on record: NCT02275351 — A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)

   ClinicalTrials.gov ↗

• NCT03742518Phase 2/3COMPLETED

  A Study Evaluating the Efficacy and Safety of SM04554 Topical Solution in Male Subjects With Androgenetic Alopecia

  Biosplice Therapeutics, Inc. · n=675 · November 2018

• NCT02503137Phase 2COMPLETED

  A Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia Analyzed by Biopsy of the Scalp Prior To and Post Dosing

  Biosplice Therapeutics, Inc. · n=49 · August 2015

• NCT02275351Phase 2COMPLETED

  A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)

  Biosplice Therapeutics, Inc. · n=310 · November 2014

Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first.

• A Study Evaluating the Efficacy and Safety of SM04554 Topical Solution in Male Subjects With Androgenetic Alopecia — ClinicalTrials.gov